Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 1;99(11):2664–2671. doi: 10.1172/JCI119455

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

K Genç 1, D L Dona 1, A T Reder 1
PMCID: PMC508112  PMID: 9169496

Abstract

Costimulatory molecules help determine T cell responses. CD80 (B7-1) and CD86 (B7-2), costimulatory proteins on antigen-presenting cells, bind to CD28 on T cells. When costimulation is coupled with a signal through the T cell receptor (TCR), T cell proliferation and cytokine secretion are induced. However, TCR signaling without CD80/CD86CD28 costimulation causes anergy. During multiple sclerosis (MS) exacerbations, circulating immune cells are activated, Th1 cytokine levels in the blood are elevated, and blood-derived immune cells destroy brain oligodendroglia. In the experimental autoimmune encephalomyelitis model of MS, CD80 on antigen-presenting cells induces Th1 cell responses; CD86 enhances generation of Th2 cells. Variation in CD80 and CD86 expression is likely to influence immune regulation in MS. We demonstrate that the number of circulating CD80(+) lymphocytes is increased significantly during MS exacerbations, but is normal in stable MS. These CD80(+) lymphocytes are predominantly B cells, based on two-color flow cytometry. The number of CD71(+) and HLA-DR+ lymphocytes and monocytes is also increased in active MS. Therapy with IFN beta-1b markedly reduces the number of circulating CD80(+) B cells and increases CD86(+) monocyte number. HLA-DR+, CD71(+), and CD25(+) mononuclear cell numbers are also reduced by therapy. The number of CD80(+) cells may be a useful surrogate marker during IFN-beta therapy, and reduction of CD80-mediated costimulation may be one therapeutic mechanism by which IFN-beta acts in MS.

Full Text

The Full Text of this article is available as a PDF (205.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antel J. P., Arnason B. G., Medof M. E. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol. 1979 Apr;5(4):338–342. doi: 10.1002/ana.410050406. [DOI] [PubMed] [Google Scholar]
  2. Bashir R. M., Whitaker J. N. Metabolism of a peptide of human myelin basic protein in the rabbit. Neurology. 1980 Nov;30(11):1184–1192. doi: 10.1212/wnl.30.11.1184. [DOI] [PubMed] [Google Scholar]
  3. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988 Oct;78(4):318–323. doi: 10.1111/j.1600-0404.1988.tb03663.x. [DOI] [PubMed] [Google Scholar]
  4. Birnbaum G., Kotilinek L. Autologous lymphocyte proliferation in multiple sclerosis and the effect of intravenous ACTH. Ann Neurol. 1981 May;9(5):439–446. doi: 10.1002/ana.410090505. [DOI] [PubMed] [Google Scholar]
  5. Bluestone J. A. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995 Jun;2(6):555–559. doi: 10.1016/1074-7613(95)90000-4. [DOI] [PubMed] [Google Scholar]
  6. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996 Jan 25;379(6563):343–346. doi: 10.1038/379343a0. [DOI] [PubMed] [Google Scholar]
  7. Byskosh P. V., Reder A. T. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996 Apr;1(5):262–269. doi: 10.1177/135245859600100502. [DOI] [PubMed] [Google Scholar]
  8. Chen C., Nabavi N. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity. 1994 May;1(2):147–154. doi: 10.1016/1074-7613(94)90108-2. [DOI] [PubMed] [Google Scholar]
  9. Correale J., Gilmore W., Lopez J., Li S. Q., McMillan M., Weiner L. P. Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis. Nat Med. 1996 Dec;2(12):1354–1360. doi: 10.1038/nm1296-1354. [DOI] [PubMed] [Google Scholar]
  10. Cross A. H., Girard T. J., Giacoletto K. S., Evans R. J., Keeling R. M., Lin R. F., Trotter J. L., Karr R. W. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 1995 Jun;95(6):2783–2789. doi: 10.1172/JCI117982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cuzner M. L., Hayes G. M., Newcombe J., Woodroofe M. N. The nature of inflammatory components during demyelination in multiple sclerosis. J Neuroimmunol. 1988 Dec;20(2-3):203–209. doi: 10.1016/0165-5728(88)90161-0. [DOI] [PubMed] [Google Scholar]
  12. De Simone R., Giampaolo A., Giometto B., Gallo P., Levi G., Peschle C., Aloisi F. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol. 1995 Mar;54(2):175–187. doi: 10.1097/00005072-199503000-00004. [DOI] [PubMed] [Google Scholar]
  13. Ding L., Linsley P. S., Huang L. Y., Germain R. N., Shevach E. M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993 Aug 1;151(3):1224–1234. [PubMed] [Google Scholar]
  14. Finck B. K., Linsley P. S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26;265(5176):1225–1227. doi: 10.1126/science.7520604. [DOI] [PubMed] [Google Scholar]
  15. Flores Villanueva P. O., Reiser H., Stadecker M. J. Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. Effect on expression of B7 and B7-2 costimulatory molecules by macrophages. J Immunol. 1994 Dec 1;153(11):5190–5199. [PubMed] [Google Scholar]
  16. Freeman G. J., Boussiotis V. A., Anumanthan A., Bernstein G. M., Ke X. Y., Rennert P. D., Gray G. S., Gribben J. G., Nadler L. M. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995 May;2(5):523–532. doi: 10.1016/1074-7613(95)90032-2. [DOI] [PubMed] [Google Scholar]
  17. Freudenthal P. S., Steinman R. M. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7698–7702. doi: 10.1073/pnas.87.19.7698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Guerder S., Meyerhoff J., Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity. 1994 May;1(2):155–166. doi: 10.1016/1074-7613(94)90109-0. [DOI] [PubMed] [Google Scholar]
  19. Hofman F. M., von Hanwehr R. I., Dinarello C. A., Mizel S. B., Hinton D., Merrill J. E. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986 May 1;136(9):3239–3245. [PubMed] [Google Scholar]
  20. June C. H., Bluestone J. A., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. Immunol Today. 1994 Jul;15(7):321–331. doi: 10.1016/0167-5699(94)90080-9. [DOI] [PubMed] [Google Scholar]
  21. Kennedy M. K., Torrance D. S., Picha K. S., Mohler K. M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol. 1992 Oct 1;149(7):2496–2505. [PubMed] [Google Scholar]
  22. Khoury S. J., Akalin E., Chandraker A., Turka L. A., Linsley P. S., Sayegh M. H., Hancock W. W. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15;155(10):4521–4524. [PubMed] [Google Scholar]
  23. Khoury S. J., Hancock W. W., Weiner H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992 Nov 1;176(5):1355–1364. doi: 10.1084/jem.176.5.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kuchroo V. K., Das M. P., Brown J. A., Ranger A. M., Zamvil S. S., Sobel R. A., Weiner H. L., Nabavi N., Glimcher L. H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995 Mar 10;80(5):707–718. doi: 10.1016/0092-8674(95)90349-6. [DOI] [PubMed] [Google Scholar]
  25. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  26. Larsen C. P., Ritchie S. C., Hendrix R., Linsley P. S., Hathcock K. S., Hodes R. J., Lowry R. P., Pearson T. C. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 1994 Jun 1;152(11):5208–5219. [PubMed] [Google Scholar]
  27. Lenschow D. J., Ho S. C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K. C., Bluestone J. A. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 Mar 1;181(3):1145–1155. doi: 10.1084/jem.181.3.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lenschow D. J., Sperling A. I., Cooke M. P., Freeman G., Rhee L., Decker D. C., Gray G., Nadler L. M., Goodnow C. C., Bluestone J. A. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994 Sep 1;153(5):1990–1997. [PubMed] [Google Scholar]
  29. Lombardi G., Sidhu S., Batchelor R., Lechler R. Anergic T cells as suppressor cells in vitro. Science. 1994 Jun 10;264(5165):1587–1589. doi: 10.1126/science.8202711. [DOI] [PubMed] [Google Scholar]
  30. Lu P., Zhou X. D., Chen S. J., Moorman M., Schoneveld A., Morris S., Finkelman F. D., Linsley P., Claassen E., Gause W. C. Requirement of CTLA-4 counter receptors for IL-4 but not IL-10 elevations during a primary systemic in vivo immune response. J Immunol. 1995 Feb 1;154(3):1078–1087. [PubMed] [Google Scholar]
  31. Miller S. D., Vanderlugt C. L., Lenschow D. J., Pope J. G., Karandikar N. J., Dal Canto M. C., Bluestone J. A. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 1995 Dec;3(6):739–745. doi: 10.1016/1074-7613(95)90063-2. [DOI] [PubMed] [Google Scholar]
  32. Noronha A., Toscas A., Jensen M. A. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993 Jul;46(1-2):145–153. doi: 10.1016/0165-5728(93)90244-s. [DOI] [PubMed] [Google Scholar]
  33. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  34. Panitch H. S. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S25–S28. doi: 10.1002/ana.410360709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Perrin P. J., Scott D., Quigley L., Albert P. S., Feder O., Gray G. S., Abe R., June C. H., Racke M. K. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol. 1995 Feb 1;154(3):1481–1490. [PubMed] [Google Scholar]
  36. Porrini A. M., Reder A. T. IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell Immunol. 1994 Sep;157(2):428–438. doi: 10.1006/cimm.1994.1239. [DOI] [PubMed] [Google Scholar]
  37. Reder A. T., Antel J. P., Oger J. J., McFarland T. A., Rosenkoetter M., Arnason B. G. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984 Aug;16(2):242–249. doi: 10.1002/ana.410160214. [DOI] [PubMed] [Google Scholar]
  38. Revel M., Chebath J., Mangelus M., Harroch S., Moviglia G. A. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler. 1995;1 (Suppl 1):S5–11. [PubMed] [Google Scholar]
  39. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Helwig A., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995 Jan;37(1):82–88. doi: 10.1002/ana.410370115. [DOI] [PubMed] [Google Scholar]
  40. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 1994 Aug;44(8):1523–1526. doi: 10.1212/wnl.44.8.1523. [DOI] [PubMed] [Google Scholar]
  41. Roth R., Nakamura T., Mamula M. J. B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J Immunol. 1996 Oct 1;157(7):2924–2931. [PubMed] [Google Scholar]
  42. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol. 1994 Jun;24(6):1434–1440. doi: 10.1002/eji.1830240629. [DOI] [PubMed] [Google Scholar]
  43. Rudick R. A., Carpenter C. S., Cookfair D. L., Tuohy V. K., Ransohoff R. M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 1993 Oct;43(10):2080–2087. doi: 10.1212/wnl.43.10.2080. [DOI] [PubMed] [Google Scholar]
  44. Rudick R. A., Ransohoff R. M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996 Oct;40(4):618–627. doi: 10.1002/ana.410400412. [DOI] [PubMed] [Google Scholar]
  45. Schiffenbauer J., Johnson H. M., Butfiloski E. J., Wegrzyn L., Soos J. M. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8543–8546. doi: 10.1073/pnas.90.18.8543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Schwartz R. H. Models of T cell anergy: is there a common molecular mechanism? J Exp Med. 1996 Jul 1;184(1):1–8. doi: 10.1084/jem.184.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sibley W. A., Bamford C. R., Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1985 Jun 8;1(8441):1313–1315. doi: 10.1016/S0140-6736(85)92801-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Verweij C. L., Geerts M., Aarden L. A. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J Biol Chem. 1991 Aug 5;266(22):14179–14182. [PubMed] [Google Scholar]
  49. Williams K., Ulvestad E., Antel J. P. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol. 1994 Dec;24(12):3031–3037. doi: 10.1002/eji.1830241217. [DOI] [PubMed] [Google Scholar]
  50. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M. N., Cuzner M. L., Hafler D. A. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995 Dec 1;182(6):1985–1996. doi: 10.1084/jem.182.6.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES